QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fda-grants-breakthrough-device-designation-for-zimmer-biomets-first-to-world-iodine-treated-total-hip-replacement-system

Prioritized Regulatory Review Process in the U.S. Follows Japan PMDA Approval in SeptemberWARSAW, Ind., Oct. 28, 2025 /PRNewswi...

 canaccord-genuity-maintains-hold-on-zimmer-biomet-holdings-maintains-101-price-target

Canaccord Genuity analyst Caitlin Roberts maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Hold and maintains $101 price t...

 btig-maintains-buy-on-zimmer-biomet-holdings-raises-price-target-to-122

BTIG analyst Ryan Zimmerman maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Buy and raises the price target from $118 to ...

 evercore-isi-group-maintains-in-line-on-zimmer-biomet-holdings-lowers-price-target-to-104

Evercore ISI Group analyst Vijay Kumar maintains Zimmer Biomet Holdings (NYSE:ZBH) with a In-Line and lowers the price targe...

 zimmer-biomet-secures-pmda-japan-approval-for-itaperloc-complete-and-ig7-hip-systems-orthopedic-implants-with-iodine-anti-bacterial-technology

iTaperloc® Complete and iG7™ Hip System with Iodine Technology inhibits bacterial adhesion and prevents biofilm formation on th...

 stifel-maintains-buy-on-zimmer-biomet-holdings-raises-price-target-to-118

Stifel analyst Rick Wise maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Buy and raises the price target from $115 to $118.

 rothschild--co-initiates-coverage-on-zimmer-biomet-holdings-with-buy-rating-announces-price-target-of-130

Rothschild & Co analyst Ed Ridley-Day initiates coverage on Zimmer Biomet Holdings (NYSE:ZBH) with a Buy rating and anno...

 rbc-capital-maintains-outperform-on-zimmer-biomet-holdings-raises-price-target-to-115

RBC Capital analyst Shagun Singh maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Outperform and raises the price target f...

 ubs-maintains-sell-on-zimmer-biomet-holdings-raises-price-target-to-96

UBS analyst Danielle Antalffy maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Sell and raises the price target from $91 t...

 raymond-james-maintains-outperform-on-zimmer-biomet-holdings-raises-price-target-to-113

Raymond James analyst Jayson Bedford maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Outperform and raises the price targ...

 zimmer-biomets-208-billion-q2-sales-ignite-orthopedic-surge-boosts-guidance-outlook

Zimmer Biomet beat Q2 estimates and raised its 2025 earnings forecast, driven by strong hip and knee sales, and new product mom...

 zimmer-biomet-holdings-raises-fy2025-adj-eps-guidance-from-790-810-to-810-830-vs-797-est-narrows-fy2025-sales-guidance-from-8117b-8309b-to-8190b-8270b-vs-8184b-est

Financial GuidanceThe Company is updating its full-year 2025 financial guidance to tighten full-year 2025 reported, constant cu...

 zimmer-biomet-holdings-q2-adj-eps-207-beats-199-estimate-sales-2077b-beat-2053b-estimate

Zimmer Biomet Holdings (NYSE:ZBH) reported quarterly earnings of $2.07 per share which beat the analyst consensus estimate of $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION